Neovasc Inc. (NVCN): Price and Financial Metrics

Neovasc Inc. (NVCN): $30.03

0.49 (+1.66%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

NVCN Price/Volume Stats

Current price $30.03 52-week high $30.07
Prev. close $29.54 52-week low $4.59
Day low $29.43 Volume 45,401
Day high $30.07 Avg. volume 56,993
50-day MA $28.96 Dividend yield N/A
200-day MA $14.15 Market Cap 82.37M

NVCN Stock Price Chart Interactive Chart >


Neovasc Inc. (NVCN) Company Bio


Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The Company also sells a line of biological tissue products that are used as components in third-party medical products including transcatheter heart valves. The company was founded in 2000 and is based in Richmond, Canada.


NVCN Latest News Stream


Event/Time News Detail
Loading, please wait...

NVCN Latest Social Stream


Loading social stream, please wait...

View Full NVCN Social Stream

Latest NVCN News From Around the Web

Below are the latest news stories about NEOVASC INC that investors may wish to consider to help them evaluate NVCN as an investment opportunity.

Why Shares of Shockwave Medical Jumped on Tuesday

Shares of Shockwave Medical (NASDAQ: SWAV) were up 10.69% early Tuesday afternoon after the Centers for Medicare and Medicaid Services (CMS) unveiled a proposed rule that detailed new payment codes for coronary intravascular lithotripsy (IVL), which is performed by a system that Shockwave manufactures. Shockwave's IVL uses sonic pressure waves to break up hardened plaque in arteries. Not only do the proposed new codes mean more money for Shockwave -- an estimated $4,000 to $5,000 more per procedure -- but it also shows that the CMS is recognizing the value of the IVL.

Yahoo | April 11, 2023

Shockwave Medical Completes Acquisition of Neovasc

SANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”). The Neovasc Reducer System (the “Reducer”) is a first-of-its-kind technology to address refractory angina. Refractory angina is a chronic condition in which a

Yahoo | April 11, 2023

Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update

VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 million in the fourth quarter of 2022 (91% growth against the fourth quarter of 2021), and $3.8 million for the full year 2022 (49% growth against fiscal 2021). · On March 13, 2023, following the conclusion of oral a

Yahoo | March 31, 2023

Neovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last year

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you...

Yahoo | March 9, 2023

Neovasc Shareholders Approve Acquisition by Shockwave Medical

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement

Yahoo | March 6, 2023

Read More 'NVCN' Stories Here

NVCN Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 49.37%
5-year -77.76%
YTD N/A
2023 0.00%
2022 34.83%
2021 -50.76%
2020 -82.41%
2019 -9.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!